Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Russano M, Cortellini A, Giusti R, Russo A, Zoratto F, Rastelli F, Gelibter A, Chiari R, Nigro O, De Tursi M, Bracarda S, Gori S, Grossi F, Bersanelli M, Calvetti L, Di Noia V, Scartozzi M, Di Maio M, Bossi P, Falcone A, Citarella F, Pantano F, Ficorella C, Filetti M, Adamo V, Veltri E, Pergolesi F, Occhipinti MA, Nicolardi L, Tuzi A, Di Marino P, Macrini S, Inno A, Ghidini M, Buti S, Aprile G, Lai E, Audisio M, Intagliata S, Marconcini R, Brocco D, Porzio G, Piras M, Rijavec E, Simionato F, Natoli C, Tiseo M, Vincenzi B, Tonini G, Santini D. Russano M, et al. Among authors: occhipinti ma. Cancer Immunol Immunother. 2022 Apr;71(4):865-874. doi: 10.1007/s00262-021-03045-9. Epub 2021 Aug 31. Cancer Immunol Immunother. 2022. PMID: 34462870 Free PMC article.
Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature.
Onesti CE, Iacono D, Angelini S, Lauro S, Mazzotta M, Occhipinti MA, Giusti R, Marchetti P. Onesti CE, et al. Among authors: occhipinti ma. Transl Lung Cancer Res. 2016 Dec;5(6):712-719. doi: 10.21037/tlcr.2016.09.01. Transl Lung Cancer Res. 2016. PMID: 28149766 Free PMC article.
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Botticelli A, Onesti CE, Zizzari I, Cerbelli B, Sciattella P, Occhipinti M, Roberto M, Di Pietro F, Bonifacino A, Ghidini M, Vici P, Pizzuti L, Napoletano C, Strigari L, D'Amati G, Mazzuca F, Nuti M, Marchetti P. Botticelli A, et al. Oncotarget. 2017 Nov 1;8(59):99336-99346. doi: 10.18632/oncotarget.22242. eCollection 2017 Nov 21. Oncotarget. 2017. PMID: 29245905 Free PMC article.
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.
Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C. Cortellini A, et al. Among authors: occhipinti ma. J Immunother Cancer. 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y. J Immunother Cancer. 2019. PMID: 30813970 Free PMC article.
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study.
Parisi A, Cortellini A, Roberto M, Venditti O, Santini D, Dell'Aquila E, Stellato M, Marchetti P, Occhipinti MA, Zoratto F, Mazzuca F, Tinari N, De Tursi M, Iezzi L, Natoli C, Ratti M, Pizzo C, Ghidini M, Porzio G, Ficorella C, Cannita K. Parisi A, et al. Among authors: occhipinti ma. J Cancer Res Clin Oncol. 2019 Sep;145(9):2365-2373. doi: 10.1007/s00432-019-02971-7. Epub 2019 Jul 6. J Cancer Res Clin Oncol. 2019. PMID: 31280347
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
Cortellini A, Vitale MG, De Galitiis F, Di Pietro FR, Berardi R, Torniai M, De Tursi M, Grassadonia A, Di Marino P, Santini D, Zeppola T, Anesi C, Gelibter A, Occhipinti MA, Botticelli A, Marchetti P, Rastelli F, Pergolesi F, Tudini M, Silva RR, Mallardo D, Vanella V, Ficorella C, Porzio G, Ascierto PA. Cortellini A, et al. Among authors: occhipinti ma. J Transl Med. 2019 Nov 15;17(1):376. doi: 10.1186/s12967-019-02132-x. J Transl Med. 2019. PMID: 31730009 Free PMC article.
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.
Cortellini A, Buti S, Bersanelli M, Giusti R, Perrone F, Di Marino P, Tinari N, De Tursi M, Grassadonia A, Cannita K, Tessitore A, Zoratto F, Veltri E, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Cappellini GCA, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Gelibter A, Occhipinti MA, Martella F, Inno A, Gori S, Bracarda S, Zannori C, Mosillo C, Parisi A, Porzio G, Mallardo D, Fargnoli MC, Tiseo M, Santini D, Ascierto PA, Ficorella C. Cortellini A, et al. Among authors: occhipinti ma. Oncoimmunology. 2020 Jan 7;9(1):1710389. doi: 10.1080/2162402X.2019.1710389. eCollection 2020. Oncoimmunology. 2020. PMID: 32002308 Free PMC article.
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, Berruti A, Falcone A, Aieta M, Gelibter A, Russo A, Barni S, Maio M, Martelli O, Pantano F, Iacono D, Calvetti L, Quadrini S, Roca E, Vasile E, Imperatori M, Occhipinti M, Galvano A, Petrelli F, Calabrò L, Pasquini G, Intagliata S, Ricciardi GRR, Tonini G, Santini D, Adamo V. Russo A, et al. Adv Ther. 2020 Mar;37(3):1145-1155. doi: 10.1007/s12325-020-01229-w. Epub 2020 Jan 30. Adv Ther. 2020. PMID: 32002809
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab.
Pantano F, Russano M, Berruti A, Mansueto G, Migliorino MR, Adamo V, Aprile G, Gelibter A, Ficorella C, Falcone A, Russo A, Aieta M, Maio M, Martelli O, Barni S, Napolitano A, Roca E, Quadrini S, Iacono D, Russo A, Calvetti L, Occhipinti MA, Cortellini A, Vasile E, Passiglia F, Imperatori M, Calabrò L, Di Giacomo AM, Petrelli F, Pasquini G, Franchina T, Venditti O, Intagliata S, Galvano A, Fioroni I, Vincenzi B, Tonini G, Santini D. Pantano F, et al. Among authors: occhipinti ma. Expert Opin Biol Ther. 2020 Mar;20(3):319-326. doi: 10.1080/14712598.2020.1724953. Epub 2020 Feb 6. Expert Opin Biol Ther. 2020. PMID: 32011207 Clinical Trial.
50 results